Haruhiko Hirate - Takeda Pharmaceutical Member Board
| TKDA Stock | EUR 12.70 0.10 0.79% |
Insider
Haruhiko Hirate is Member Board of Takeda Pharmaceutical
| Age | 66 |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | INSIDER Age | ||
| Cameron Esq | New Residential Investment | 47 | |
| Varun Wadhawan | New Residential Investment | N/A | |
| David Yates | WisdomTree Investments | 43 | |
| Alexis Marinof | WisdomTree Investments | 47 | |
| Ben Slavin | WisdomTree Investments | N/A | |
| Jeremy CFA | WisdomTree Investments | N/A | |
| Charles Sorrentino | New Residential Investment | N/A | |
| CFA CFA | New Residential Investment | 51 | |
| BoHee Yoon | New Residential Investment | N/A | |
| Sanjeev Khanna | New Residential Investment | N/A | |
| Jessica Zaloom | WisdomTree Investments | N/A | |
Management Performance
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christophe Weber, CEO Pres | ||
| Christopher OReilly, Global Fin | ||
| Andrew Plump, Pres Director | ||
| Seigo Izumo, Chair Board | ||
| Gabriele Ricci, Chief Officer | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Sr Department | ||
| Constantine Saroukos, CFO Director | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 71.66 B | |||
| Shares Outstanding | 3.12 B | |||
| Shares Owned By Institutions | 2.23 % | |||
| Price To Earning | 29.55 X | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 0.01 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Takeda Stock
Takeda Pharmaceutical financial ratios help investors to determine whether Takeda Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takeda with respect to the benefits of owning Takeda Pharmaceutical security.